Sign in

Elanco Animal Health Inc (ELAN) Q4 2022 Earnings Summary

Executive Summary

  • Q4 2022 revenue was $0.99B (down 11% YoY, -6% CER), with adjusted EPS of $0.19 and adjusted EBITDA of $174M (17.6% margin). Reported EPS was $(0.11) driven by special charges and tax items .
  • Mix and macro headwinds persisted (OTC pet retail softness in U.S./Europe, China recovery lag, FX), while price and productivity partially offset pressure; gross margin improved 70 bps YoY to 54.7% .
  • FY23 guidance introduced: revenue $4.28B–$4.40B, adjusted EBITDA $920M–$1,000M, adjusted EPS $0.74–$0.83; 1H23 revenue $2.23B–$2.31B and adjusted EPS $0.43–$0.50, reflecting ERP cutover phasing and continued macro pressure .
  • Strategic catalysts highlighted: U.S. FDA approval path by 1H24 for late‑stage blockbusters (broad‑spectrum parasiticide, JAK inhibitor, IL‑31 mAb) and Bovaer; Bexacat approved; OTC relaunches (Advantage, K9 Advantix) to target value segment .

What Went Well and What Went Wrong

What Went Well

  • Price and productivity supported margins despite lower sales; gross margin rose to 54.7% (+70 bps YoY) on price and manufacturing productivity .
  • Pipeline progressed: Bexacat approved; submissions initiated/advanced for JAK inhibitor and broad‑spectrum parasiticide; FDA path for Bovaer to potential 1H24 launch; OTC relaunches received EPA approvals .
  • Management confidence in 2023 setup and “historic launch window”; focus on ERP go‑live, commercial and launch excellence (“we have confidence in this '23 guide… business returning to growth in the second half”) .

What Went Wrong

  • Pet Health revenue declined 14% YoY in Q4 (−10% CER) on OTC retail weakness in U.S./Europe, competitive pressure in parasiticides, supply constraints in some vaccines, and retailer destocking .
  • Farm Animal declined 9% YoY (−3% CER) as U.S. cattle was impacted by vaccine supply constraints and distributor purchasing reductions; poultry declined on U.S. rotation timing; swine declined outside the U.S. .
  • Adjusted EBITDA margin compressed to 17.6% (−160 bps YoY) on lower volume/mix and inflation despite price tailwind; net leverage held at 5.4x as EBITDA softened and cash balances were lower than expected at year‑end .

Financial Results

Headline metrics: Q4 2021 vs Q3 2022 vs Q4 2022

MetricQ4 2021Q3 2022Q4 2022
Revenue ($M)$1,113 $1,028 $988
Reported EPS$(0.21) $(0.10) $(0.11)
Adjusted EPS$0.21 $0.20 $0.19
Adjusted EBITDA ($M)$214 $205 $174
Adjusted EBITDA Margin19.2% 19.9% 17.6%
Gross Margin %—54.1% 54.7%

Notes: Gross margin % is reported/adjusted gross profit as a % of revenue per company presentation .

Segment revenue (Q4)

Segment ($M)Q4 2021Q4 2022YoY ChangeCER Change
Pet Health$494 $423 (14)% (10)%
Farm Animal$604 $552 (9)% (3)%
- Cattle$245 $222 (9)% (5)%
- Poultry$208 $187 (10)% (4)%
- Swine$118 $100 (15)% (10)%
- Aqua$33 $43 +30% +42%
Contract Manufacturing$15 $13 (13)% (5)%
Total Revenue$1,113 $988 (11)% (6)%

Additional KPIs and P&L line items (Q4 2022)

KPIQ4 2022Context
Gross Profit ($M) and GM%$540; 54.7% +70 bps YoY on price/productivity offsetting inflation/mix
Operating Expenses ($M)$383 MS&A $303 (−7% YoY); R&D $80 (−13% YoY)
Asset Impairment/Restructuring/Other ($M)$32 Integration/system implementation costs (Bayer AH)
Net Interest Expense ($M)$62 reported; $61 adjusted Higher variable rates and incremental term facilities
Reported Effective Tax Rate39.4% Adjusted ETR −22.0% (various items)
Cash from Operations ($M)~$10–$20 (expected) Lower vs $223M in Q4’21 on inventory build/ERP cutover phasing
Net Leverage Ratio5.4x adjusted EBITDA Flat vs YE21; net debt reduction offset EBITDA decline

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenue ($B)FY 2023—$4.28–$4.40 New
Reported Net Income (Loss) ($M)FY 2023—$(157)–$(109) New
Adjusted EBITDA ($M)FY 2023—$920–$1,000 New
Reported EPSFY 2023—$(0.32)–$(0.22) New
Adjusted EPSFY 2023—$0.74–$0.83 New
Revenue ($B)1H 2023—$2.23–$2.31 New
Reported Net Income (Loss) ($M)1H 2023—$(53)–$(22) New
Adjusted EBITDA ($M)1H 2023—$490–$540 New
Reported EPS1H 2023—$(0.11)–$(0.04) New
Adjusted EPS1H 2023—$0.43–$0.50 New

Additional guidance color:

  • FY23 FX headwind ~$10–$15M; constant currency revenue flat to −3%; ERP go‑live causes ~$40–$80M shift of legacy Bayer product orders into Q1 from Q2 .
  • FY23 adjusted EPS decline vs 2022 driven by higher floating‑rate interest expense and higher tax rate; price >2% and innovation contribution ($210–$250M; +$80–$120M incremental) are partial offsets .

Earnings Call Themes & Trends

TopicQ2 2022 (Aug)Q3 2022 (Nov)Q4 2022 (Feb)Trend
Supply chainPaper/packaging issues resolved; lingering CMO/input constraints; expect better in 2023 Stabilizing; some U.S. cattle vaccine constraints Internal supply constraints cited in U.S. cattle vaccines; easing expected in 2023 Improving operationally; isolated constraints persist
ChinaExpected bounce-back slowed; 2022 outlook cut (Pet and Swine) Continued pressure; China Pet Health − prior hopes moderated Q4 grew 9% CER; improving but cautious on pork prices/consumer confidence Recovery signs emerging
OTC retail parasiticidesU.S./EU retail softness; trade spend shift OTC market down, retailer destocking; expect stabilization into 2023 Value relaunches (Advantage/K9 Advantix); targeting cost‑conscious consumer Refresh + value strategy to mitigate macro
Competitive innovationVet parasiticide pressure; BRD dynamics Full‑year competitive impact ~$100M Competitive pressures to remain similar to 2022 Ongoing headwind
PricingFY22 ~2% with back‑half step‑up Price +3% in Q4; +2% FY22; more than 2% in FY23 Expect >2% FY23 Positive lever
ERP integrationMid‑2023 target Pulled forward to early Q2’23 Go‑live April; order blackout shifts Q2 into Q1 Execution milestone
Pipeline (Pet Health)Submissions in 2–4 months; Zorbium launch; feline diabetes in‑licensed Broad‑spectrum and JAK rolling submissions; IL‑31 submission planned 1H23 Bexacat approved; 1H24 approval path for parasiticide, JAK, IL‑31; launch prep underway De‑risking/advancing
Regulatory (Seresto/EPA)Continued defense of safety profile Expect constructive EPA stewardship outcome in 2023 —Toward resolution

Management Commentary

  • CEO framing: “Our late-stage innovation is on track, and we continue to see a path towards U.S. approval of 5 potential blockbuster products by the first half of 2024… we now anticipate a first half 2024 U.S. approval and launch of Bovaer” .
  • 2023 setup: “We expect revenue to be between $4.28 billion and $4.4 billion… adjusted EPS of $0.74 to $0.83” .
  • OTC/value strategy: “We’re relaunching the original formulation of Advantage… and K9 Advantix… positioned as value offerings that capture the cost‑conscious consumer” .
  • Confidence in guidance: “We do see this challenging environment persisting into the first half… we do have confidence in this ’23 guide… business returning to growth in the second half” .
  • Margin/expense discipline: “Operating expenses declined 9% year‑over‑year… Adjusted EBITDA margin was 17.6%… including a $0.07 benefit from a favorable fourth quarter tax rate” .

Q&A Highlights

  • OTC vs Rx strategy and Seresto: Management stressed an omnichannel approach; expects an “improving year for Seresto in ’23” supported by physical availability, price and geography; EPA engagement described as constructive with expected 2023 outcome .
  • Cash/Leverage: Year‑end 2023 leverage guided to 5.3x–5.9x; ~$100M net paydown contemplated assuming working capital improvement; no covenant concerns (covenants >7x) .
  • Innovation contribution: FY23 innovation revenue expected $220–$250M; broad‑spectrum parasiticide positioned as differentiated; focus on launch readiness in 2023 .
  • 1H vs 2H cadence: ERP order blackout shifts legacy Bayer revenue to Q1 from Q2; EBITDA cadence tougher in 1H given retail OTC seasonality and recessionary pressure; expect 2H improvement .
  • Gross margin and mix: Margin impacted by Pet Health weakness and inflation; management still expects improvement over time with innovation and retail refresh .

Estimates Context

  • We attempted to retrieve Wall Street consensus (S&P Global) for Q4 2022 revenue and EPS but could not due to data access limits. As a result, we cannot state beat/miss versus external consensus at this time.
  • Company guidance comparison: Q4 2022 results were within revenue guidance ($955–$1,000M) and adjusted EBITDA guidance ($165–$200M), and adjusted EPS ($0.19) exceeded the $0.10–$0.16 guidance range provided in November 2022 .

Key Takeaways for Investors

  • Fundamentals: Q4 delivered in line on revenue and EBITDA, with EPS above company guidance despite macro/mix headwinds; gross margin expanded YoY on price/productivity .
  • Mix headwinds vs offsets: OTC pet retail and competitive parasiticides remain pressure points; management leans on price (>2% in 2023), pipeline commercialization, and retail value relaunches to offset .
  • 2023 guide realistic with phasing: ERP transition drives intra‑half shifts; macro pressures persist into 1H; management expects return to growth in 2H, with innovation and price as key drivers .
  • Balance sheet: Net leverage at 5.4x; company targeting modest net debt reduction in 2023; floating‑rate exposure keeps interest expense elevated until de‑levering accelerates .
  • Pipeline‑led re‑rating potential: Multiple late‑stage assets targeting 1H24 approvals (parasiticide, JAK, IL‑31, Bovaer) and near‑term launches (Bexacat, OTC relaunches) provide catalysts that can reshape mix and margins .
  • Watch items: Retail sell‑through/stock levels in flea/tick season, China demand normalization, supply normalization in U.S. cattle vaccines, and EPA outcome for Seresto .

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%